A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial.

Autor: Alkema M; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands., Smit MJ; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands., Marin-Mogollon C; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands., Totté K; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands., Teelen K; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands., van Gemert GJ; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands., van de Vegte-Bolmer M; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands., Mordmüller BG; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands., Reimer JM; Novavax AB, Uppsala, Sweden., Lövgren-Bengtsson KL; Novavax AB, Uppsala, Sweden., Sauerwein RW; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.; Present Address: TropIQ Health Sciences, Nijmegen, the Netherlands., Bousema T; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands., Plieskatt J; Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark., Theisen M; Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark.; Centre for Medical Parasitology at Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark., Jore MM; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands., McCall MBB; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands. matthew.mccall@radboudumc.nl.
Jazyk: angličtina
Zdroj: BMC medicine [BMC Med] 2024 Apr 23; Vol. 22 (1), pp. 170. Date of Electronic Publication: 2024 Apr 23.
DOI: 10.1186/s12916-024-03379-y
Abstrakt: Background: The stalling global progress in malaria control highlights the need for novel tools for malaria elimination, including transmission-blocking vaccines. Transmission-blocking vaccines aim to induce human antibodies that block parasite development in the mosquito and mosquitoes becoming infectious. The Pfs48/45 protein is a leading Plasmodium falciparum transmission-blocking vaccine candidate. The R0.6C fusion protein, consisting of Pfs48/45 domain 3 (6C) and the N-terminal region of P. falciparum glutamate-rich protein (R0), has previously been produced in Lactococcus lactis and elicited functional antibodies in rodents. Here, we assess the safety and transmission-reducing efficacy of R0.6C adsorbed to aluminium hydroxide with and without Matrix-M™ adjuvant in humans.
Methods: In this first-in-human, open-label clinical trial, malaria-naïve adults, aged 18-55 years, were recruited at the Radboudumc in Nijmegen, the Netherlands. Participants received four intramuscular vaccinations on days 0, 28, 56 and 168 with either 30 µg or 100 µg of R0.6C and were randomised for the allocation of one of the two different adjuvant combinations: aluminium hydroxide alone, or aluminium hydroxide combined with Matrix-M1™ adjuvant. Adverse events were recorded from inclusion until 84 days after the fourth vaccination. Anti-R0.6C and anti-6C IgG titres were measured by enzyme-linked immunosorbent assay. Transmission-reducing activity of participants' serum and purified vaccine-specific immunoglobulin G was assessed by standard membrane feeding assays using laboratory-reared Anopheles stephensi mosquitoes and cultured P. falciparum gametocytes.
Results: Thirty-one participants completed four vaccinations and were included in the analysis. Administration of all doses was safe and well-tolerated, with one related grade 3 adverse event (transient fever) and no serious adverse events occurring. Anti-R0.6C and anti-6C IgG titres were similar between the 30 and 100 µg R0.6C arms, but higher in Matrix-M1™ arms. Neat participant sera did not induce significant transmission-reducing activity in mosquito feeding experiments, but concentrated vaccine-specific IgGs purified from sera collected two weeks after the fourth vaccination achieved up to 99% transmission-reducing activity.
Conclusions: R0.6C/aluminium hydroxide with or without Matrix-M1™ is safe, immunogenic and induces functional Pfs48/45-specific transmission-blocking antibodies, albeit at insufficient serum concentrations to result in transmission reduction by neat serum. Future work should focus on identifying alternative vaccine formulations or regimens that enhance functional antibody responses.
Trial Registration: The trial is registered with ClinicalTrials.gov under identifier NCT04862416.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: